Navigation Links
New Funding Validates Importance of Divergence's Work on Nematodes
Date:2/9/2010

Divergence receives grant funding of $500,000 to prevent crop damage by nematodes as the Divergence and National Corn Growers Association continues collaboration.

(PRWEB) February 9, 2010 -- Divergence, Inc. announced today that the company has recently received two Small Business Innovation Research (SBIR) grants totaling $500,000, along with renewed funding from the National Corn Growers Association (NCGA), to support advancement of the company’s innovative work to prevent crop damage from nematodes. Parasitic nematode worms are the largest unsolved pest problem in agriculture, limiting the yield of crops worldwide and causing tens of billions of dollars in crop damage annually.

The U.S. Department of Agriculture (USDA) and the National Science Foundation (NSF) both awarded grants to the company, while the NCGA announced continuation of its funding to support work on nematode control in corn. The USDA issued a Phase II grant of $350,000 for development of crops with resistance to root knot nematodes. The NSF provided a Phase I grant of $150,000 for the development of novel, safe and effective nematicidal chemicals for crops, turf and ornamental plants discovered through Divergence’s powerful research platform, Harvest®.

“This combination of funding is a validation of the substantial progress Divergence has made in demonstrating the performance of our technologies in protecting crops from parasitic nematode damage,” said James P. McCarter, M.D., Ph.D., President and Chief Scientific Officer of Divergence. “We are excited at the possibilities for meeting growers’ and greens superintendants’ needs with an array of products, whether used alone or in an integrated fashion. Our portfolio of complementary biotechnology traits and agrochemicals with superior human and environmental safety offer outstanding potential to meet market needs for higher yielding and sustainable agriculture.”

The grant from the NSF is the third that Divergence has received based on Harvest®. “Harvest® is a revolutionary proprietary platform technology with broad utility in the development of agrochemicals and is the source of Divergence’s lead nematicide,” said McCarter. “The platform allows for more rapid and cost effective discovery of novel fungicides, insecticides and herbicides, as well as nematicides. Divergence is applying the platform to internal and collaboration projects in multiple product categories. We are confident of our continued discovery of leads that work through highly effective modes of action not currently used in commercial products. This progress is important as concerns of safety and resistance in a variety of markets increase.”

Divergence is also pleased to continue its productive relationship with NCGA. The collaboration, now in its eighth year, has successfully discovered technology with the potential to protect corn from the yield-reducing effects of parasitic nematode infection. “It is gratifying that NCGA believes in the great importance and high quality of the research being conducted at Divergence,” said McCarter. “The advancement of our work in the last year makes us increasingly confident that growers will have one or more safe and effective approaches to significantly reduce the damage to corn done by parasitic nematodes. These developments should lead to products for other major crop markets, as well.”

About Divergence
Divergence, Inc., a world leader in the application of genomics and informatics to agriculture and infectious disease, discovers and develops products for the safe and effective control of parasites. The company's initial focus is on parasitic nematodes, devastating unseen pests that cause billions of dollars in crop loss annually and widespread disease in humans and animals. The company’s innovative research platforms have broad potential for the discovery of superior products for sustainable food production and improved human and animal health. For more information visit Divergence's Web site at www.divergence.com.

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3584224.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. NVHR: Stop Liver Cancer Dead in Its Tracks By Closing Funding Gap for Viral Hepatitis Education, Screening Programs
2. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
3. Zimmer Holdings Announces 2010 Funding for OMeGA Medical Grants Association
4. A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs
5. Palmer Labs Awarded U.S. Department of Energy Funding for Algae Biofuel Research
6. Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project
7. The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinsons Disease Treatments
8. Zyngenia, Inc. Raises $10 Million in Series A Funding
9. Collaboration of Indianas Health Information Exchanges, State Organizations Submits Application for Health Information Technology Stimulus Funding
10. BioNanomatrix Awarded Supplemental Funding to Accelerate Commercialization of Innovative Single-Molecule Analyzer
11. Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... $7M Series B financing, adding an additional $3M from ... by Mesa Verde Venture Partners and other strategic partners ... directed towards further accelerating commercial adoption of their flagship ... test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
Breaking Biology Technology:
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):